We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current TVTX market cap is 1.59B. The company's latest EPS is USD -1.4273 and P/E is -14.22.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | -16.51M | 45.06M | 41.37M | 54.12M | 62.9M |
| Operating Income | -127.87M | -94.23M | -139.24M | -67.7M | -56.15M |
| Net Income | 150.74M | -90.17M | -136.06M | -70.41M | -54.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 193.34M | 198.32M | 227.49M | 212.02M | 145.24M |
| Operating Income | -122.36M | -176.16M | -161.77M | -266.57M | -388.14M |
| Net Income | -146.43M | -169.43M | -180.09M | -278.48M | -111.4M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 832.85M | 788.91M | 663.55M | 551.12M | 504.41M |
| Total Liabilities | 553.08M | 588.1M | 589.48M | 535.97M | 534.86M |
| Total Equity | 279.77M | 200.81M | 74.07M | 15.15M | -30.45M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 604.8M | 607.44M | 776.63M | 672.59M | 788.91M |
| Total Liabilities | 383.6M | 396.23M | 474.52M | 629.73M | 588.1M |
| Total Equity | 221.2M | 211.21M | 302.11M | 42.85M | 200.81M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -209.55M | -280.02M | -119.01M | -159.25M | -201.76M |
| Investing | 72.73M | 55.78M | 104.9M | 133.51M | 179.63M |
| Financing | 218.63M | 218.75M | -525k | 257k | 303k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -58.21M | -42.74M | -14.79M | -186.29M | -280.02M |
| Investing | 19.86M | -61.33M | -137.62M | -32.55M | 55.78M |
| Financing | -2.08M | 127.71M | 231.68M | 117.57M | 218.75M |
| Market Cap | 1.59B |
| Price to Earnings Ratio | -14.22 |
| Price to Sales Ratio | 10.9 |
| Price to Cash Ratio | 27.22 |
| Price to Book Ratio | 7.89 |
| Dividend Yield | - |
| Shares Outstanding | 78.05M |
| Average Volume (1 week) | 1.57M |
| Average Volume (1 Month) | 1.18M |
| 52 Week Change | 115.38% |
| 52 Week High | 20.33 |
| 52 Week Low | 5.12 |
| Spread (Intraday) | 0.63 (3.01%) |
| Company Name | Travere Therapeutics Inc |
| Address |
16192 coastal hwy lewes, delaware 19958 |
| Website | https://travere.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
